Diabetes Mellitus, Type 2NCT04041492
Effect of Vitamins D3 and K2 in uOc and Insulin Serum Levels in Patients With Diabetes Mellitus
A study testing Supplementation with Vitamin D3 y K2 in people with Diabetes Mellitus, Type 2 and Bone Loss, run by University of Guadalajara at 1 site in Mexico.
Trial summary
Introduction: Patients with DM2 have chronic hyperglycemia derived from a decrease in insulin sensitivity, cause of comorbidities such as bone demineralization, decreasing quality of life and increasing mortality. Read more about this study
- Who is it for?
- Ages 30 to 75 years
- Conditions the study is for
- Diabetes Mellitus, Type 2, Bone Loss, Insulin Resistance
- What is being tested?
- Supplementation with Vitamin D3 y K2
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteMexico
- Study dates
- 14 Feb 2017to 14 Feb 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Originating and residents of Western Mexico
- Both genres
- Age of 30-75 years
- Diagnosis of DM2 (ADA Criteria) of at least 5 years of evolution
- Sign an informed consent letter.
Who cannot join
- Use of active drugs for bone mineralization
- Pregnancy
- Lactation
- Creatinine or transaminase more than double the upper limit
- Diet added with calcium or vitamins (D, K).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of Supplementation With Vitamins D3 and K2 in Non-carboxyled Osteocalcine and Insulin Serum Levels in Patients With Diabetes Mellitus Type 2
Introduction: Patients with DM2 have chronic hyperglycemia derived from a decrease in insulin sensitivity, cause of comorbidities such as bone demineralization, decreasing quality of life and increasing mortality. This could be related to changes in the serum levels of carboxylated Osteocalcin and Insulin, together with the deficit the daily consumption of vitamins D3 and K, which is crucial for the process of mineralization of the bone matrix.
Research question: What is the effect of supplementation with Vitamins D3 and K2 on serum levels of Carboxylated Osteocalcin and Insulin in patients with Type 2 Diabetes mellitus?
Read more
Hypothesis: Supplementation with Vitamins D3 and K2 modifies the serum levels of Carboxylated Osteocalcin and Insulin in patients with Type 2 Diabetes mellitus.
General Objectives: To assess the effect of supplementation with Vitamins D3 and K2 on serum levels of Carboxylated and Non-Carboxylated Osteocalcin in patients with Type 2 Diabetes mellitus.
Material and Methods: Clinical trial, double blind, randomization, 40 patients with DM2, 35-65 years, supplementation (3 months), clinical and laboratory determinations (uOC and Insulin).
- Group 1: Vitamin D3 1000UI + Placebo
- Group 2: Vitamin K2 100 mcg + Placebo
- Group 3 (Positive Control): Vitamins D3 1000UI + K2 100 mcg
Read the detailed description
Type 2 diabetes mellitus is a group of metabolic disorders characterized by chronic hyperglycemia, being one of the main causes of mortality in our country.
There are different comorbidities, including bone demineralization, which involve an imbalance in the process of bone formation and resorption, which entails the risk of decreasing bone mineral density. These processes could be related to the serum levels of Non-carboxylated Osteocalcin and Insulin, said molecule locally modulates the process of bone mineralization.
On the other hand, it is known that the daily consumption of vitamins in a general diet in our population (specifically including vitamins D3 and K), is below the necessary basic requirements, so considering crucial elements for the benefit of Bone matrix mineralization, which is why the present study proposes supplementation with the aforementioned vitamins in patients with Type 2 DM, to avoid a decrease in bone mineral density, increasing the mortality rate of individuals suffering from it.
- - The study subjects from the West of the country were invited to participate in the research protocol, where their objective was explained and the signing of the consent was requested under information, where a structured evaluation was subsequently carried out consisting of :
- Comprehensive clinical evaluation (including general sociodemographic data of a complete medical history).
- - Once the previous data was obtained, the randomization of the treatment was carried out, classifying the patients in the following groups:
- Group 1 Vitamin D3 1000UI + Placebo (Calcined Magnesia).
- Group 2 Vitamin K2 100 mcg + Placebo (Calcined Magnesia).
- Group 3 (Positive Control) Vitamins D3 1000UI + K2 100 mcg.
- - Blood sample collection through Punzocat, which was placed in a red tube, for subsequent centrifugation at 3500rpm x 15 minutes, performing aliquots of the serum obtained and stored at -80 ° C and thus perform the pertinent quantifications of the molecules to study.
- - Quantification of serum levels of non-carboxylated Osteocalcin and Insulin
- The determinations corresponding to the serum levels of Non-carboxylated Osteocalcin and Insulin were made, both baseline prior to the intervention as well as the final quantification, once the supplementation was finished, by means of the indirect ELISA technique (commercial reagents -Takara were used - for the realization of these determinations), which involved the following process: In a plate the wells were coated with a first antibody, then a wash was performed to remove the excess antibody, after that, the sample in which the antigen was found was added, which was retained in the well after being recognized by the first antibody, a second wash was subsequently made to remove unbound material, then a solution with a second labeled anti-antigen antibody was applied. Thus each antigen molecule was bound to an antibody in the base that kept it fixed and a second antibody for its reaction and labeling. Finally, the plate was introduced into a spectophotometer and the absorbance was measured at a length of 450 nm, for both non-carboxylated Osteocalcin and Insulin.
- - The quantification in serum of cholesterol and triglycerides was carried out by using the fully automated random access analyzer equipment for clinical chemistry, model ERBA XL 200.
- - The evaluation of the HOMA index was calculated by using the equations HOMA-IR and HOMA-B, for insulin resistance (IR) and Percentage, respectively.
- - The daily of adherence to treatment was provided, so that they recorded all those important events that would ensure adequate intake of vitamins, as well as adverse reactions to them, which were evaluated in scheduled appointments, in addition to each The corresponding bottles were delivered consecutively for each of the 3 months of intervention, with the corresponding vitamins for each patient according to their allocation group.
- - Finally, in the last visit the results obtained during the whole study were made known to each of the patients.
- Conditions
- Diabetes Mellitus, Type 2, Bone Loss, Insulin Resistance
- Being tested
- Supplementation with Vitamin D3 y K2
- Keywords
- diabetes, osteocalcin, insulin
- Medical subject headings
- Diabetes Mellitus, Type 2, Bone Diseases, Metabolic, Insulin Resistance, Diabetes Mellitus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Supplementation with Vitamin D3 y K2Dietary supplement
Supplementation at a dose of 1 capsule every 24 hours x 3 months
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | Experimental | Vitamin D3 1000UI + Placebo (Calcined Magnesia). Receives: Dietary Supplement: Supplementation with Vitamin D3 y K2 |
| Group 2 | Experimental | Vitamin K2 100 mcg + Placebo (Calcined Magnesia). Receives: Dietary Supplement: Supplementation with Vitamin D3 y K2 |
| Group 3 | Active comparator | Vitamin D3 1000UI + Vitamin K2 100 mcg Receives: Dietary Supplement: Supplementation with Vitamin D3 y K2 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Non-carboxylated osteocalcin
Serum levels
Measured: 3 months
Insulin
Serum levels
Measured: 3 months
Secondary outcomes (4)
Weight
kg
Measured: 3 months
Height
m
Measured: 3 months
Body mass index
Quetelet index
Measured: 3 months
HOMA Index
Insulin resistance
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Aug 2019
- Study start14 Feb 2017
- Primary completion14 Feb 2018
- Study completion14 Feb 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Diabetes Mellitus, Type 2Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Single group
- Model description
- Controlled clinical trial, with randomization simple, double blind.
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Guadalajara
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Julio Ivan Aguayo Ruiz, University of Guadalajara
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04041492
- Sponsor's protocol ID
- F-2017-1702-14
- Status last verified
- Jul 2019
- First submitted
- 31 Jul 2019
- Last updated
- 2 Aug 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Non-sharable data
Publications
Salinas-Varela Y, Barajas-Gonzalez MA, Martinez-Lopez E, Llamas-Covarrubias IM, Lopez-Quintero A, Sanchez-Enriquez S, Rivera-Leon EA. Association between the VKORC1 rs8050894 CC genotype and undercarboxylated osteocalcin levels following vitamin K and D supplementation in Mexican Citizens with T2DM: A randomized clinical trial. J Investig Med. 2026 Jun 8:10815589261460882. doi: 10.1177/10815589261460882. Online ahead of print.
PubMed 42257367Aguayo-Ruiz JI, Garcia-Cobian TA, Pascoe-Gonzalez S, Sanchez-Enriquez S, Llamas-Covarrubias IM, Garcia-Iglesias T, Lopez-Quintero A, Llamas-Covarrubias MA, Trujillo-Quiroz J, Rivera-Leon EA. Effect of supplementation with vitamins D3 and K2 on undercarboxylated osteocalcin and insulin serum levels in patients with type 2 diabetes mellitus: a randomized, double-blind, clinical trial. Diabetol Metab Syndr. 2020 Aug 18;12:73. doi: 10.1186/s13098-020-00580-w. eCollection 2020.
PubMed 32831908
Study at a glance
From the registry record, last updated by the sponsor on 2 Aug 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Supplementation With Vitamins D3 and K2 in Non-carboxyled Osteocalcine and Insulin Serum Levels in Patients With Diabetes Mellitus Type 2
- ClinicalTrials.gov ID
- NCT04041492
- Acronym / sponsor ID
- F-2017-1702-14
- Conditions
- Diabetes Mellitus, Type 2, Bone Loss, Insulin Resistance
- Keywords
- diabetes, osteocalcin, insulin
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- University of GuadalajaraUniversity, hospital or other
- Study start
- 14 Feb 2017 (actual)
- Primary completion
- 14 Feb 2018 (actual)
- Study completion
- 14 Feb 2019 (actual)
- First posted
- 1 Aug 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Introduction: Patients with DM2 have chronic hyperglycemia derived from a decrease in insulin sensitivity, cause of comorbidities such as bone demineralization, decreasing quality of life and increasing mortality. This could be related to changes in the serum levels of carboxylated Osteocalcin and Insulin, together with the deficit the daily consumption of vitamins D3 and K, which is crucial for the process of mineralization of the bone matrix.
Research question: What is the effect of supplementation with Vitamins D3 and K2 on serum levels of Carboxylated Osteocalcin and Insulin in patients with Type 2 Diabetes mellitus?
Hypothesis: Supplementation with Vitamins D3 and K2 modifies the serum levels of Carboxylated Osteocalcin and Insulin in patients with Type 2 Diabetes mellitus.
General Objectives: To assess the effect of supplementation with Vitamins D3 and K2 on serum levels of Carboxylated and Non-Carboxylated Osteocalcin in patients with Type 2 Diabetes mellitus.
Material and Methods: Clinical trial, double blind, randomization, 40 patients with DM2, 35-65 years, supplementation (3 months), clinical and laboratory determinations (uOC and Insulin).
- Group 1: Vitamin D3 1000UI + Placebo
- Group 2: Vitamin K2 100 mcg + Placebo
- Group 3 (Positive Control): Vitamins D3 1000UI + K2 100 mcg
Detailed description
Type 2 diabetes mellitus is a group of metabolic disorders characterized by chronic hyperglycemia, being one of the main causes of mortality in our country.
There are different comorbidities, including bone demineralization, which involve an imbalance in the process of bone formation and resorption, which entails the risk of decreasing bone mineral density. These processes could be related to the serum levels of Non-carboxylated Osteocalcin and Insulin, said molecule locally modulates the process of bone mineralization.
On the other hand, it is known that the daily consumption of vitamins in a general diet in our population (specifically including vitamins D3 and K), is below the necessary basic requirements, so considering crucial elements for the benefit of Bone matrix mineralization, which is why the present study proposes supplementation with the aforementioned vitamins in patients with Type 2 DM, to avoid a decrease in bone mineral density, increasing the mortality rate of individuals suffering from it.
- - The study subjects from the West of the country were invited to participate in the research protocol, where their objective was explained and the signing of the consent was requested under information, where a structured evaluation was subsequently carried out consisting of :
- Comprehensive clinical evaluation (including general sociodemographic data of a complete medical history).
- - Once the previous data was obtained, the randomization of the treatment was carried out, classifying the patients in the following groups:
- Group 1 Vitamin D3 1000UI + Placebo (Calcined Magnesia).
- Group 2 Vitamin K2 100 mcg + Placebo (Calcined Magnesia).
- Group 3 (Positive Control) Vitamins D3 1000UI + K2 100 mcg.
- - Blood sample collection through Punzocat, which was placed in a red tube, for subsequent centrifugation at 3500rpm x 15 minutes, performing aliquots of the serum obtained and stored at -80 ° C and thus perform the pertinent quantifications of the molecules to study.
- - Quantification of serum levels of non-carboxylated Osteocalcin and Insulin
- The determinations corresponding to the serum levels of Non-carboxylated Osteocalcin and Insulin were made, both baseline prior to the intervention as well as the final quantification, once the supplementation was finished, by means of the indirect ELISA technique (commercial reagents -Takara were used - for the realization of these determinations), which involved the following process: In a plate the wells were coated with a first antibody, then a wash was performed to remove the excess antibody, after that, the sample in which the antigen was found was added, which was retained in the well after being recognized by the first antibody, a second wash was subsequently made to remove unbound material, then a solution with a second labeled anti-antigen antibody was applied. Thus each antigen molecule was bound to an antibody in the base that kept it fixed and a second antibody for its reaction and labeling. Finally, the plate was introduced into a spectophotometer and the absorbance was measured at a length of 450 nm, for both non-carboxylated Osteocalcin and Insulin.
- - The quantification in serum of cholesterol and triglycerides was carried out by using the fully automated random access analyzer equipment for clinical chemistry, model ERBA XL 200.
- - The evaluation of the HOMA index was calculated by using the equations HOMA-IR and HOMA-B, for insulin resistance (IR) and Percentage, respectively.
- - The daily of adherence to treatment was provided, so that they recorded all those important events that would ensure adequate intake of vitamins, as well as adverse reactions to them, which were evaluated in scheduled appointments, in addition to each The corresponding bottles were delivered consecutively for each of the 3 months of intervention, with the corresponding vitamins for each patient according to their allocation group.
- - Finally, in the last visit the results obtained during the whole study were made known to each of the patients.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 3
- Model description
- Controlled clinical trial, with randomization simple, double blind.
| Arm | Type | Receives |
|---|---|---|
| Group 1 | Experimental | Dietary Supplement: Supplementation with Vitamin D3 y K2Vitamin D3 1000UI + Placebo (Calcined Magnesia). |
| Group 2 | Experimental | Dietary Supplement: Supplementation with Vitamin D3 y K2Vitamin K2 100 mcg + Placebo (Calcined Magnesia). |
| Group 3 | Active comparator | Dietary Supplement: Supplementation with Vitamin D3 y K2Vitamin D3 1000UI + Vitamin K2 100 mcg |
Who may qualify
- Ages
- 30 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Originating and residents of Western Mexico
- Both genres
- Age of 30-75 years
- Diagnosis of DM2 (ADA Criteria) of at least 5 years of evolution
- Sign an informed consent letter.
Key exclusion criteria (5 listed)
- Use of active drugs for bone mineralization
- Pregnancy
- Lactation
- Creatinine or transaminase more than double the upper limit
- Diet added with calcium or vitamins (D, K).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Supplementation with Vitamin D3 y K2Supplementation at a dose of 1 capsule every 24 hours x 3 months | Dietary supplement | Group 1, Group 2, Group 3 |
Primary outcome
Non-carboxylated osteocalcin
Time frame: 3 months
Serum levels
Insulin
Time frame: 3 months
Serum levels
4 secondary outcomes
Weight
Time frame: 3 months
Height
Time frame: 3 months
Body mass index
Time frame: 3 months
HOMA Index
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Aug 2019.
- Derived from this study: PubMed 42257367Salinas-Varela Y, Barajas-Gonzalez MA, Martinez-Lopez E, Llamas-Covarrubias IM, Lopez-Quintero A, Sanchez-Enriquez S, Rivera-Leon EA. Association between the VKORC1 rs8050894 CC genotype and undercarboxylated osteocalcin levels following vitamin K and D supplementation in Mexican Citizens with T2DM: A randomized clinical trial. J Investig Med. 2026 Jun 8:10815589261460882. doi: 10.1177/10815589261460882. Online ahead of print.
- Derived from this study: PubMed 32831908Aguayo-Ruiz JI, Garcia-Cobian TA, Pascoe-Gonzalez S, Sanchez-Enriquez S, Llamas-Covarrubias IM, Garcia-Iglesias T, Lopez-Quintero A, Llamas-Covarrubias MA, Trujillo-Quiroz J, Rivera-Leon EA. Effect of supplementation with vitamins D3 and K2 on undercarboxylated osteocalcin and insulin serum levels in patients with type 2 diabetes mellitus: a randomized, double-blind, clinical trial. Diabetol Metab Syndr. 2020 Aug 18;12:73. doi: 10.1186/s13098-020-00580-w. eCollection 2020.
- Individual participant dataSharing planned: No. Non-sharable data
Related trials for Diabetes Mellitus, Type 2
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Supplementation with Vitamin D3 y K2 in people with Diabetes Mellitus, Type 2 and Bone Loss, run by University of Guadalajara at 1 site in Mexico.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Aug 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Non-carboxylated osteocalcin (time frame: 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04041492, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Aug 2019.